公开(公告)号：US20240197703A1

公开(公告)日：2024-06-20

申请号：US18144737

申请日：2023-05-08

Applicant: PFIZER INC.

Inventor： Joyann Barber ,  Sujin Cho-Schultz ,  Matthew L. Del Bel ,  Rebecca Anne Gallego ,  Mingying He ,  Mehran Jalaie ,  Robert Steven Kania ,  Michele Ann McTigue ,  Sajiv Krishnan Nair ,  Anne-Marie Dechert Schmitt ,  Jamison Bryce Tuttle ,  Dahui Zhou ,  Ru Zhou

IPC: A61K31/444 ,  A61K45/06 ,  C07D471/04 ,  C07D519/00

CPC classification number: A61K31/444 ,  A61K45/06 ,  C07D471/04 ,  C07D519/00

Abstract: This invention relates to compounds of general Formula I






and pharmaceutically acceptable salts thereof, in which R1, R2, R3a, R3b, and R4 are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

公开(公告)号：US11142525B2

公开(公告)日：2021-10-12

申请号：US16679820

申请日：2019-11-11

Applicant: Pfizer Inc.

Inventor： Rebecca Anne Gallego ,  Sajiv Krishnan Nair ,  Robert Steven Kania ,  Omar Khaled Ahmad ,  Ted William Johnson ,  Jamison Bryce Tuttle ,  Mehran Jalaie ,  Michele Ann McTigue ,  Dahui Zhou ,  Matthew L. Del Bel ,  Ru Zhou ,  Mingying He ,  Anne-Marie Dechert Schmitt

IPC: C07D471/04 ,  A61P35/00

Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R1a, R2, R3, R4, and (R5)a are as defined herein, to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable salts thereof, and to methods of using such compounds, pharmaceutically acceptable salts and compositions for the treatment of abnormal cell growth, including cancer.

公开(公告)号：US11684616B2

公开(公告)日：2023-06-27

申请号：US17246551

申请日：2021-04-30

Applicant: PFIZER INC.

Inventor： Joyann Barber ,  Sujin Cho-Schultz ,  Matthew L. Del Bel ,  Rebecca Anne Gallego ,  Mingying He ,  Mehran Jalaie ,  Robert Steven Kania ,  Michele Ann McTigue ,  Sajiv Krishnan Nair ,  Anne-Marie Dechert Schmitt ,  Jamison Bryce Tuttle ,  Dahui Zhou ,  Ru Zhou

IPC: C07D471/04 ,  C07D519/00 ,  A61K31/444 ,  A61K45/06

CPC classification number: A61K31/444 ,  A61K45/06 ,  C07D471/04 ,  C07D519/00

Abstract: This invention relates to compounds of general Formula I






and pharmaceutically acceptable salts thereof, in which R1, R2, R3a, R3b, and R4 are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

公开(公告)号：US20200172539A1

公开(公告)日：2020-06-04

申请号：US16679820

申请日：2019-11-11

Applicant: Pfizer Inc.

Inventor： Rebecca Anne Gallego ,  Sajiv Krishnan Nair ,  Robert Steven Kania ,  Omar Khaled Ahmad ,  Ted William Johnson ,  Jamison Bryce Tuttle ,  Mehran Jalaie ,  Michele Ann McTigue ,  Dahui Zhou ,  Matthew L. Del Bel ,  Ru Zhou ,  Mingying He

IPC: C07D471/04 ,  A61P35/00

Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R1a, R2, R3, R4, and (R5)a are as defined herein, to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable salts thereof, and to methods of using such compounds, pharmaceutically acceptable salts and compositions for the treatment of abnormal cell growth, including cancer.

公开(公告)号：US20250122183A1

公开(公告)日：2025-04-17

申请号：US18903849

申请日：2024-10-01

Applicant: Pfizer Inc. ,  CTXT PTY LTD

Inventor： Alexander Burtea ,  Michael Raymond Collins ,  Matthew L. Del Bel ,  Samantha Elizabeth Greasley ,  Eric Johnson ,  Ted William Johnson ,  Robert Arnold Kumpf ,  Pei-Pei Kung ,  Timothy Patrick Montgomery ,  Sacha Ninkovic ,  Gwenaella Christine Rescourio ,  Paul Francis Richardson ,  Stephanie Anne Scales ,  Scott Channing Sutton

IPC: C07D413/14 ,  A61K31/423 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/501 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  C07D413/12 ,  C07D471/04

Abstract: The present invention relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein Ring A, Ring B, R1—R16, n and p are defined herein. The novel nitrogen-linked benzisoxazole sulfonamide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in patients. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth, such as cancer, in patients.

公开(公告)号：US20220401424A1

公开(公告)日：2022-12-22

申请号：US17246551

申请日：2021-04-30

Applicant: PFIZER INC.

Inventor： Joyann Barber ,  Sujin Cho-Schultz ,  Matthew L. Del Bel ,  Rebecca Anne Gallego ,  Mingying He ,  Mehran Jalaie ,  Robert Steven Kania ,  Michele Ann McTigue ,  Sajiv Krishnan Nair ,  Anne-Marie Dechert Schmitt ,  Jamison Bryce Tuttle ,  Dahui Zhou ,  Ru Zhou

IPC: A61K31/444 ,  A61K45/06 ,  C07D519/00 ,  C07D471/04

Abstract: This invention relates to compounds of general Formula I and pharmaceutically acceptable salts thereof, in which R1, R2, R3a, R3b, and R4 are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.